Novel pyrrolidinium compounds having antagonistic activity against muscarinic receptors and use thereof

EP4688739A1Pending Publication Date: 2026-02-11EFLASK CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
EP2024781148
Authority / Receiving Office
EP · EP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-03-27
Filing Date
2024-03-25
Publication Date
2026-02-11

AI Technical Summary

Technical Problem

Current muscarinic receptor antagonists are inadequate in effectively treating muscarinic acetylcholine receptor-mediated diseases, particularly those involving muscarinic M3 receptors, such as hyperhidrosis and asthma, due to limitations in antagonistic activity and specificity.

Method used

A novel pyrrolidinium compound with a specific chemical structure, represented by Formula I, is developed, which exhibits excellent antagonistic activity against muscarinic M3 receptors, allowing for the creation of a pharmaceutical composition for preventing or treating these diseases.

Benefits of technology

The compound demonstrates significant antagonistic activity against muscarinic M3 receptors, as evidenced by its IC50 values at the nM level, effectively inhibiting acetylcholine binding and providing therapeutic benefits for conditions like hyperhidrosis, asthma, and other muscarinic acetylcholine receptor-mediated diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2024003671_03102024_PF_FP_ABST
    Figure KR2024003671_03102024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a novel pyrrolidinium compound, a stereoisomer, hydrate, or solvate thereof, which exhibits excellent binding ability and antagonistic activity to muscarinic receptors, especially muscarinic M3 receptors. The compound of the present invention is useful in the treatment of a muscarinic acetylcholine receptor-mediated disease, such as hyperhidrosis, hypersalivation, chronic obstructive pulmonary disease, chronic bronchitis, asthma, rhinitis, urinary incontinence, overactive bladder syndrome, gastroesophogeal reflux disease, and irritable bowel syndrome, etc.
Need to check novelty before this filing date? Find Prior Art